Enable Injections, Inc. (“Enable”) a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery ...

Global drugmakers face a battle in 2026 to secure higher prices for their prescription medicines in Europe after agreeing to ...

Proceeds to fund clinical development of DIAG723, a first-in-class, disease-modifying therapy designed to correct the root cause of hereditary hemorrhagic telangiectasia and pulmonary arterial ...

With a $125 million series B financing round, Diagonal Therapeutics has made a vertical move to advance its first-in-class ...

It sounds like Lilly did just that. The U.S. pharma announced on Wednesday that it was paying $14 per share of Ventyx—more ...

Oregon’s attorney general filed a lawsuit Wednesday against three insulin manufacturers and the nation’s largest pharmacy ...

The hefty funding will fuel Phase 2 testing of a drug with a similar mechanism to Amgen’s closely watched obesity drug, as ...

The deals tout significant discounts for people who pay out of pocket for certain medications. But most people with insurance ...

Backed by more than a dozen prominent investors, the startup is advancing into human testing a drug it believes capable of ...

Barclays analyst Shirley Chen downgraded Sanofi to a Hold today and set a price target of €85.00. According to TipRanks, Chen is ranked #4918 out of 10355 analysts.

ALV-100 is a bifunctional glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist / glucagon-like peptide-1 receptor (GLP-1R) agonist fusion protein designed to deliver potent, durable ...

Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, designed for sustained efficacy, improved tolerability, and ...